Centrexion rakes in $67 mln Series D in NEA-led round
Boston-based Centrexion Therapeutics Corporation, a developer of treatments for chronic pain, has closed $67 million in Series D financing. New Enterprise Associates led the round with participation from other investors that included Quan Capital, ArrowMark Partners, certain investment funds advised by Clough Capital Partners L.P., InterWest Partners, 6 Dimensions Capital and Efung Capital. In conjunction with the funding, Centrexion has appointed Dr. Sara Nayeem, a partner at NEA, and Dr. Stella Xu, a managing director at Quan Capital, to its board of directors. Leerink Partners LLC was financial adviser on the transaction.
2 January 2018•1 min read
